

PROGRESS REPORT

CENTRE OF EXCELLENCE IN PRECISION THERAPEUTICS

New Cohorts for PMT

Exactis with the help of the PI Coordinating Committee has revised the recruitment criteria for the PMT registry. This update reflects our current priorities to rapidly profile and match patients to precision oncology clinical trials. We have phased out early disease in favor of advanced and metastatic diseases. Finally, we have added bladder and endometrial cancer, only at Sunnybrook and the Jewish General Hospital to help support the recruitment of the Merck MK-7339-002 protocol.

	Melanoma	CRC	Lung	Breast	Prostate	Ovarian	Bladder	Endometrial
Sub-Types	Cutaneous Mucosal	Any	Non-small cell lung cancer (NSCLC)	Any	Any	Any	Any	Any
Stage	IIc III IV	III IV	I II III IV	III IV	IV	III IV	III IV	III IV

Welcome Queen Elizabeth II to the Network!

Exactis welcomes the 12th site to the network. Under the leadership of Dr Zhaolin Xu (Pulmonary Pathologist and Cytologist at the QEII Health Sciences Centre) and Dr. Drew Bethune (Senior Medical Director of the Cancer Care Program at Nova Scotia Health Authority), the QEII site will be recruiting primarily lung as a first cohort. Congratulations to John Fris (PMT Coordinator) on recruiting your 34th patient since Nov14th!



3rd Annual PICC Meeting

Exactis Innovation was pleased to host the 2019 Annual face-to-face meeting of the Principal Investigator Coordinating Committee (PICC) on Sept 20th, 2019. The meeting featured highly interactive discussions between experts on network collaboration, patient engagement and current themes in clinical oncology research. We would like to thank our PICC Chair, Dr. Helen MacKay and all of the Experts for being part of this successful meeting and we look forward to another year of progress and collaboration.

Welcome Diana Salazar to the Exactis Team!

1

Diana Salazar has recently joined the team as Clinical Operations Manager. Diana has over 6 years experience managing clinical trials in cardiovascular, chronic viral and infectious diseases. Diana completed a Bachelor's degree in Biology (Genetics) at the University of Antioquia, (Colombia), a Master of Science (Molecular Biology) at the University of Québec in Montréal and a M.B.A in Pharmaceutical Management at Laval University. She has previously worked as a Project Manager in different CROs, Academic and Health Organizations



MERCK MK-7339-002

Merck is looking to enroll patients with advanced solid tumors with Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) in Canada. They require that sites do local testing to confirm the mutation status before a patient can be consented to the project. Exactis will be involved in the pre-screening testing of patients to be enrolled study at Sunnybrook and JGH by profiling tissue samples from PMT participants.

EXACTIS PROGRESS REPORT

CENTER OF EXCELLENCE IN PRECISION THERAPEUTICS

Exactis-01 Lung Blood Study

The Exactis-01 study "Multi-centre Observational Study to Evaluate the Clinical Utility of Returning Genomic Aberration results Using the Oncomine Precision Assay (OPA) in Advanced or Metastatic NSCLC" will be open at several PMT sites and Princess Margaret Hospital. The main objective is to demonstrate the non-inferiority of the OPA vs. SOC. Blood and/or tissue will be profiled and results will be returned to the treating oncologist. The study is pending REB approval and anticipate study activation by Feb 2020.

TRAM-01 Study

Exactis is managing the TRAM-01 study which is a phase II study in pediatric low-grade glioma or plexiform neurofibroma with refractory tumour and activation of the MAPK/ERK pathway treated with trametinib. Recruitment remains strong with 52 out of 150 patients enrolled. Sites are ahead of recruitment! So far, there are 36 responders. Congrats to the TRAM team!



For up to date information about Exactis, subscribe to our LinkedIn page. Here, you will find information about our projects, clinical research tips, majors news in the field of precision oncology, information on our partners and more. It's a great way to stay in touch between newsletters.

<https://www.linkedin.com/company/exactis/>

Season's Greetings and Holiday Closure

The Exactis office will be closed for the holiday season from December 20th to January 5th inclusively. We would like to wish peace, joy, and hope to All.

Happy Holidays and a Happy New Year!




AACR Special Conference on Advances in Liquid Biopsies!


Exactis will be presenting a poster at AACR Advances in Liquid Biopsies in Jan 2020. The title is "Sequential ctDNA analysis detected relapse in patients with metastatic colorectal cancer from the Exactis trial (NCT00984048)". This study was based on a research collaboration with Contextual Genomics, a Canadian Biotechnology Company.

PMT Stats

5138 participants
12 sites
5 provinces
6 health networks
8 cancer types



Number of participants recruited per site



Distribution of Cancer Types in PMT